The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.

Cellular therapy developer Gamida Cell, which counts Novartis as its largest investor, has filed for a $69m initial public offering.

Merck & Co and Takeda are in line for exits when drug developer NGM Biopharmaceuticals lists on the Nasdaq Global Select Market.

The SIG China-backed mobile app developer raised $52.2m despite floating at the bottom of the IPO's range.

Liulishuo has listed on the New York Stock Exchange following a $71.9m initial public offering that provided an exit to publishing house Hearst.

The Eli Lilly-backed immuno-oncology product developer floated at the top of its range, with Bluebird Bio investing $10m.

Immunotherapy developer Sutro Biopharma has floated on the Nasdaq Global Market, providing exits for Merck & Co, Celgene, Amgen and Eli Lilly.

The lending platform's existing shareholders, which include Rocket Internet, sold $184m in shares as part of the offering.

The underwriters for the initial public offering have bought another $27m in shares in the Alphabet and Salesforce-backed online survey platform developer.

Sutro Biopharma, an immunotherapy developer commercialising technology created at Stanford University, has floated on the Nasdaq Global Market.